title: Elderly ovarian cancer: treatment with mitoxantrone-carboplatin.
abstract: OBJECTIVE
  Data concerning optimal treatment of elderly patients with ovarian cancer are scanty. The management of ovarian cancer in the aged patient is many-sided: the diagnosis can be difficult and delayed, and aggressive surgery is often not attempted because of concomitant morbidity. We tested a combination of carboplatin and mitoxantrone potentially associated with low toxicity in elderly patients with ovarian cancer.
  
  
  METHODS
  Eighty-two patients older than 70 years (median age, 75; range, 70-88) with epithelial ovarian cancer were referred to our multicenter group and enrolled into this pilot study. Carboplatin (JM8) was given at the dose of 230 mg/m2 and mitoxantrone at the dose of 9 mg/m2 every 28 days.
  
  
  RESULTS
  Dose-limiting toxicity was represented by 4 cases of thrombocytopenia and 1 case of gastrointestinal toxicity. These 5 episodes occurred in 328 assessable cycles, representing a low toxicity profile (3%). Of the 68 assessable patients, 36 (53%) did not respond to chemotherapy (no change + progressive disease), complete response was observed in 15 (22%), and partial remission was observed in 16 (23.5%), accounting for an overall response rate of 45%.
  
  
  CONCLUSIONS
  The carboplatin-mitoxantrone combination, at the dosage tested in this study, appears to be well tolerated by elderly patients with advanced ovarian cancer and is associated with an acceptable response rate. Optimally debulked patients also showed improved survival when compared with patients with more extensive tumor.
authors.affiliation: Department of Medical Oncology, City Hospital, Padua, Italy. mariaorn@libero.it
authors.forename: M O
authors.initials: MO
authors.lastname: Nicoletto
authors.forename: G
authors.initials: G
authors.lastname: Artioli
authors.forename: M
authors.initials: M
authors.lastname: Donach
authors.forename: V C
authors.initials: VC
authors.lastname: Sileni
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
authors.forename: R
authors.initials: R
authors.lastname: Talamini
authors.forename: A
authors.initials: A
authors.lastname: Veronesi
authors.forename: E
authors.initials: E
authors.lastname: Ferrazzi
authors.forename: S
authors.initials: S
authors.lastname: Tumolo
authors.forename: E
authors.initials: E
authors.lastname: Visonà
authors.forename: M
authors.initials: M
authors.lastname: Amichetti
authors.forename: L
authors.initials: L
authors.lastname: Endrizzi
authors.forename: L
authors.initials: L
authors.lastname: Salvagno
authors.forename: A
authors.initials: A
authors.lastname: Prosperi
authors.forename: P
authors.initials: P
authors.lastname: Azzoni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects
chemical_list: D016190:Carboplatin; D008942:Mitoxantrone